Anhui Fengyuan Pharmaceutical operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Anhui Fengyuan Pharmaceutical with three other
companies in this sector in CHINA :
Jiuzhitang Company Limited
sales of 3.18 billion Chinese Renmimbi [US$458.36 million]
of which 88%
was Pharmacuetical Industry),
Chengdu Kanghong Pharmaceutical Group Co Ltd
(3.26 billion Chinese Renmimbi [US$468.94 million]
of which 100%
was Pharmaceutical Manufacturing), and
Heilongjiang ZBD Pharmaceutical Co Ltd
(3.29 billion Chinese Renmimbi [US$473.92 million]
of which 62%
was Pharmaceutical Industry).
During the year ended December of 2019, sales at
Anhui Fengyuan Pharmaceutical were 3.24 billion Chinese Renmimbi (US$466.18 million).
increase of 7.5%
versus 2018, when the company's sales were 3.01 billion Chinese Renmimbi.
This was the fourth straight year of sales growth at Anhui Fengyuan Pharmaceutical.
Sales of Medicine Retail Circulation saw an increase
that was more than double the company's growth rate: sales were up
18.2% in 2019, from
1.29 billion Chinese Renmimbi to 1.53 billion Chinese Renmimbi.
Anhui Fengyuan Pharmaceutical also saw significant increases in sales in
Other Operations (up 11.1% to 62.93 million Chinese Renmimbi)
Not all segments of Anhui Fengyuan Pharmaceutical experienced an increase in sales in 2019:
sales of Medicine Manufacturing fell 1.1% to 1.65 billion Chinese Renmimbi.